Company: Cleveland BioLabs
Starting stock price: $4.78
Ending stock price: $8.80
Percent Change: 84.10%
Details: Cleveland BioLabs is a spin-off of the famed Cleveland Clinic. The company is developing drugs using its mechanistic discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. Cleveland BioLabs is conduction clinical trials of Curaxin CBLC102 prostate cancer, CBLC102 for renal cell carcinoma, and CBLB502 for acute radiation syndrome.
Cleveland Clinic spinoff goes public. Report